British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.
Tag Archive for: Merck KGaA
British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.